MCID: MSL001
MIFTS: 61

Measles

Categories: Infectious diseases, Rare diseases, Skin diseases, Smell/Taste diseases

Aliases & Classifications for Measles

Summaries for Measles

MedlinePlus : 43 Measles is an infectious disease caused by a virus. It spreads easily from person to person. It causes a blotchy red rash. The rash often starts on the head and moves down the body. Other symptoms include Fever Cough Runny nose Conjunctivitis (pink eye) Feeling achy and run down Tiny white spots inside the mouth Sometimes measles can lead to serious problems. There is no treatment for measles, but the measles-mumps-rubella (MMR) vaccine can prevent it. "German measles", also known as rubella, is a completely different illness. Centers for Disease Control and Prevention

MalaCards based summary : Measles, also known as morbilli, is related to rubella and mumps, and has symptoms including fever, cough and conjunctivitis. An important gene associated with Measles is CD46 (CD46 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Sodium citrate and Amodiaquine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and t cells, and related phenotypes are no effect and hematopoietic system

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Measles virus, which is transmitted by contact with oronasal secretions, or semen of an infected person. The infection has symptom fever, has symptom cough, has symptom coryza, has symptom conjunctivitis, and has symptom maculopapular, erythematous rash.

CDC : 3 Measles is a highly contagious virus that can lead to complications.

Wikipedia : 75 Measles is a highly contagious infectious disease caused by the measles virus. Symptoms usually develop... more...

Related Diseases for Measles

Diseases related to Measles via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 682)
# Related Disease Score Top Affiliating Genes
1 rubella 33.5 IFNAR2 HLA-A DDX58 CD40LG
2 mumps 33.1 STAT1 IFNG IFNAR2 CD46
3 encephalitis 32.4 TLR3 DDX58 CD209
4 variola major 31.6 TLR3 IFNG
5 stomatitis 31.4 EIF2AK2 DDX58 ADAR
6 dengue virus 30.8 IFIH1 DDX58 CD209
7 herpes simplex 30.7 TLR3 IFNB1 IFIH1 EIF2AK2 DDX58 CD209
8 japanese encephalitis 30.6 TLR3 STAT1 IFNB1 DDX58 CD209
9 west nile virus 30.6 TLR3 IFIH1 DDX58 CD209
10 bacterial infectious disease 30.5 TLR3 TLR2 IFNG
11 severe acute respiratory syndrome 30.3 STAT1 IFNG IFNB1 CD209
12 influenza 30.2 TLR3 IFNG IFNB1 IFIH1 EIF2AK2 DDX58
13 mouth disease 30.1 TLR3 STAT1 IFNG
14 neisseria meningitidis infection 30.1 TLR2 MSN CD46
15 demyelinating disease 30.0 IFNG IFNB1 CD40LG
16 human immunodeficiency virus type 1 30.0 TLR3 STAT1 IFNG HLA-A CD209 ADAR
17 mycobacterium tuberculosis 1 29.9 TLR2 IFNG CD209
18 hepatitis c virus 29.9 IFNG IFIH1 EIF2AK2 DDX58
19 toxoplasmosis 29.7 TLR2 IFNG CD40LG
20 dengue hemorrhagic fever 29.1 TLR3 STAT1 IFNG HLA-A CD209
21 viral infectious disease 29.1 TLR3 STAT1 IFNG IFNB1 IFIH1 EIF2AK2
22 malaria 28.7 TLR2 IFNG HLA-A FCGR2B CD40LG
23 systemic lupus erythematosus 28.3 TLR2 STAT1 SLAMF1 IFNG IFNB1 HLA-DMA
24 panencephalitis, subacute sclerosing 12.4
25 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 12.2
26 congenital rubella 11.7
27 acute disseminated encephalomyelitis 11.6
28 croup 11.5
29 postinfectious encephalomyelitis 11.5
30 striatonigral degeneration, infantile 11.4
31 acute hemorrhagic leukoencephalitis 11.4
32 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.1
33 immunodeficiency 45 11.1
34 subacute thyroiditis 11.1
35 microcephaly 11.1
36 immune-mediated encephalomyelitis 11.1
37 exanthem 11.0
38 chickenpox 10.9
39 poliomyelitis 10.8
40 pertussis 10.7
41 diphtheria 10.7
42 tetanus 10.7
43 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.6
44 multiple sclerosis 10.6
45 pneumonia 10.6
46 diarrhea 10.6
47 conjunctivitis 10.6
48 autism 10.6
49 marburg hemorrhagic fever 10.6 IFNB1 CD209
50 vaccinia 10.6

Graphical network of the top 20 diseases related to Measles:



Diseases related to Measles

Symptoms & Phenotypes for Measles

Symptoms:

12
  • fever
  • cough
  • conjunctivitis
  • coryza
  • maculopapular

UMLS symptoms related to Measles:


fever, pruritus, exanthema, koplik spots

GenomeRNAi Phenotypes related to Measles according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ADAR CD209 CD40LG CD46 DDX58 EIF2AK2

MGI Mouse Phenotypes related to Measles:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 ADAR CD40LG DDX58 EIF2AK2 FCGR2B HLA-DMA
2 immune system MP:0005387 10.1 ADAR CD40LG DDX58 EIF2AK2 FCGR2B HLA-DMA
3 mortality/aging MP:0010768 9.73 ADAR CD40LG DDX58 EIF2AK2 FCGR2B HLA-DMA
4 liver/biliary system MP:0005370 9.7 ADAR DDX58 FCGR2B IFIH1 IFNG STAT1
5 neoplasm MP:0002006 9.23 DDX58 EIF2AK2 IFNAR2 IFNB1 IFNG STAT1

Drugs & Therapeutics for Measles

Drugs for Measles (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
3
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
4
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
5
Lumefantrine Approved Phase 4 82186-77-4 6437380
6
Artemether Approved Phase 4 71963-77-4 68911 119380
7
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
8
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
9
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
10
BCG vaccine Investigational Phase 4
11 Vaccines Phase 4
12 Anti-Infective Agents Phase 4
13 Antimalarials Phase 4
14 Antiparasitic Agents Phase 4
15 Antiprotozoal Agents Phase 4
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
17 Adjuvants, Immunologic Phase 4
18 Citrate Phase 4
19 Anthelmintics Phase 4
20 Gastrointestinal Agents Phase 4
21 Cathartics Phase 4
22 Laxatives Phase 4
23 Artemether, Lumefantrine Drug Combination Phase 4
24 Antibiotics, Antitubercular Phase 4
25 insulin Phase 4
26 Insulin, Globin Zinc Phase 4
27 Antiviral Agents Phase 4
28
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
29
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
30
Sulfamethoxazole Approved Phase 3 723-46-6 5329
31
Zinc Approved, Investigational Phase 3 7440-66-6 32051
32
Terlipressin Approved, Investigational Phase 3 14636-12-5 72081
33
Petrolatum Approved, Investigational Phase 3 8009-03-8
34
Podophyllin Approved Phase 3 9000-55-9
35
leucovorin Approved Phase 3 58-05-9 143 6006
36
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
37
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
38
Proguanil Approved Phase 3 500-92-5 4923
39
Dapsone Approved, Investigational Phase 3 80-08-0 2955
40
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
41
Chlorproguanil Investigational Phase 3 537-21-3 151170 9571037
42 Anti-Inflammatory Agents Phase 3
43 Anti-Allergic Agents Phase 3
44 Trimethoprim, Sulfamethoxazole Drug Combination Phase 3
45 Cytochrome P-450 Enzyme Inhibitors Phase 3
46 Hemagglutinins Phase 3
47 taxane Phase 3
48 Somatomedin B Phase 3
49 PENTA Phase 3
50 Anti-Bacterial Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 256)
# Name Status NCT ID Phase Drugs
1 A Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality and to Explore the Role of Maternal Measles Antibodies for the Beneficial Non-specific Effects of Measles Vaccine Unknown status NCT01486355 Phase 4
2 Assessing Immunogenicity of Measles-Rubella Vaccine at 6 and 9 Months of Age Unknown status NCT03071575 Phase 4
3 Induction and Maintenance of Immunity Against Measles in Pediatric Orthotopic Liver Transplantation Recipients: a Prospective Nationwide Study in Switzerland Unknown status NCT01770119 Phase 4
4 The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age Unknown status NCT01306006 Phase 4
5 A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau Unknown status NCT01644721 Phase 4
6 A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau Unknown status NCT01668745 Phase 4
7 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Unknown status NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
8 Randomised Trial of Vitamin A Supplementation Given With Routine Childhood Vaccines at National Immunisation Days Unknown status NCT00168623 Phase 4 Vitamin A
9 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
10 Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries? Randomized Prospective Studies in Guinea-Bissau Unknown status NCT00168610 Phase 4 Vitamin A
11 Non-interference and Safety of Concomitant Administration of Measles-rubella and Rotavirus Vaccines at 9 Months of Age in Rural Bangladesh Completed NCT01700621 Phase 4
12 Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Completed NCT03680417 Phase 4
13 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
14 Trial of Two-Dose Standard Measles Vaccination Schedule: Long-Term Impact on Morbidity and Mortality of a Two-Dose Vaccination Schedule at 6 and 9 Months of Age Compared With a Standard Regimen of One Dose at 9 Months of Age Completed NCT00168662 Phase 4
15 Long-term Follow-up of Protective Measles Antibodies in the Two-dose Study of Standard-titre Measles Vaccine in Guinea-Bissau Completed NCT00168571 Phase 4
16 Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
17 Measles Vaccination in Guinea-Bissau. Strategies to Reduce Disease Burden and Improve Child Survival Completed NCT00168558 Phase 4
18 Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children Completed NCT00313950 Phase 4
19 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
20 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
21 An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age Completed NCT00312858 Phase 4
22 An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age Completed NCT00326183 Phase 4
23 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine Completed NCT02325310 Phase 4
24 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
25 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
26 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
27 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age. Completed NCT01777529 Phase 4
28 Comparison of Immunization Schedules of Beijing Tiantan Biological's MMR Vaccine in 18-72 Month-Old Children Completed NCT03160820 Phase 4
29 Seroprevalence of Antibodies to Measles, Mumps, and Rubella, and Serologic Responses After Vaccination Among Human Immunodeficiency Virus (HIV)-1 Infected Adults in Northern Thailand Completed NCT02724852 Phase 4
30 Immunogenicity of Co-administration of Measles Containing Vaccine and Japanese Encephalitis Alive Vaccines Completed NCT02643433 Phase 4
31 Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka Completed NCT00463684 Phase 4
32 Diphteria-tetanus-pertussis (DTP) Vaccination and Child Survival: Randomized Study of Not Providing DTP Vaccination Together With or After Measles Vaccination Completed NCT00244673 Phase 4
33 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
34 A Phase IV, Non-Inferiority, Observer Blind Randomized Clinical Study Comparing Safety And Immunogenicity Of MMR Subcutaneous Vaccination By Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe For The Administration In Healthy Children In India Aged 15 To 18 Months Completed NCT02253407 Phase 4
35 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
36 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
37 The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection Completed NCT03453801 Phase 4
38 Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries? Completed NCT00168597 Phase 4 Vitamin A
39 An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
40 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
41 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
42 A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children Completed NCT02385513 Phase 4
43 Randomized, Controlled Clinical Trial of Day-care Based and Hospitalized Management of Severe and Very Severe Pneumonia, With Severe Malnutrition, With/Without Associated Co-morbidities in Children Completed NCT00968370 Phase 4
44 In Vivo Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria: an Open-randomised, Non-inferiority Clinical Trial in South Kivu, DR Congo Completed NCT02741024 Phase 4 Amodiaquine-Artesunate (ASAQ);Artemether-Lumefantrine (AL)
45 Measles-mumps-rubella Vaccine at 6 Months of Age, Immunology, and Childhood Morbidity in a High-income Setting Recruiting NCT03780179 Phase 4
46 A Cluster Randomized Controlled Trial on the Campaign Effect of Measles Vaccine and Oral Polio Vaccine on General Hospital Admissions and Mortality Among Children Recruiting NCT03460002 Phase 4
47 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine in HIV-exposed and HIV-unexposed South African Children Recruiting NCT03330171 Phase 4
48 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
49 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Recruiting NCT03519568 Phase 4
50 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Enrolling by invitation NCT03296410 Phase 4

Search NIH Clinical Center for Measles

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Measles virus strain enders' attenuated edmonston live antigen
Mumps virus strain b level jeryl lynn live antigen
Rubella virus vaccine

Cochrane evidence based reviews: measles

Genetic Tests for Measles

Anatomical Context for Measles

MalaCards organs/tissues related to Measles:

41
Testes, Brain, T Cells, Bone, Skin, Eye, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Measles:

19
Skin

Publications for Measles

Articles related to Measles:

(show top 50) (show all 22406)
# Title Authors PMID Year
1
Comment on "Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality". 38 17
31296741 2019
2
Response to Comment on "Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality". 38 17
31296742 2019
3
Measles outbreak investigation in an urban slum of Kaduna Metropolis, Kaduna State, Nigeria, March 2015. 38 17
31303921 2019
4
Measles virus-induced immunosuppression in SLAM knock-in mice. 9 38
20200244 2010
5
Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. 9 38
20071568 2010
6
Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150). 9 38
20042501 2010
7
Development and evaluation of a rapid immunochromatographic test for mumps-specific IgM in oral fluid specimens and use as a matrix for preserving viral nucleic acid for RT-PCR. 9 38
20087926 2010
8
Restriction analysis of otosclerosis-associated CD46 splicing variants. 9 38
19597833 2010
9
Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor. 9 38
19806178 2009
10
Laboratory confirmation of measles in elimination settings: experience from the Republic of the Marshall Islands, 2003. 9 38
19274360 2009
11
Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. 9 38
19007958 2009
12
Interplay between virus-specific effector response and Foxp3 regulatory T cells in measles virus immunopathogenesis. 9 38
19319188 2009
13
Disease-associated novel CD46 splicing variants and pathologic bone remodeling in otosclerosis. 9 38
18677279 2008
14
Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population. 9 38
18715339 2008
15
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. 9 38
18559536 2008
16
High-density rafts preferentially host the complement activator measles virus F glycoprotein but not the regulators of complement activation. 9 38
18455798 2008
17
Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants. 9 38
18419254 2008
18
Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. 9 38
18325643 2008
19
[Host genetic factors for the development of SSPE]. 9 38
17695285 2007
20
Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. 9 38
17695519 2007
21
Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. 9 38
17492596 2007
22
Downregulation of human CD46 by adenovirus serotype 35 vectors. 9 38
17377598 2007
23
Expression of measles virus receptors in otosclerotic, non-otosclerotic and in normal stapes footplates. 9 38
17294206 2007
24
Current problems of measles control in Japan and Western Pacific Region. 9 38
17368662 2007
25
Cytosolic 5'-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. 9 38
17356690 2007
26
Measles virus-dendritic cell interaction via SLAM inhibits innate immunity: selective signaling through TLR4 but not other TLRs mediates suppression of IL-12 synthesis. 9 38
17070884 2007
27
A case of common variable immunodeficiency syndrome associated with Takayasu arteritis. 9 38
17304891 2007
28
Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infection. 9 38
17135325 2007
29
Detection of circulating antigen with a MAb-based sandwich-ELISA and its comparison with specific IgM detection in sera of patients with hemorrhagic fever with renal syndrome. 9 38
17316085 2007
30
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. 9 38
17133484 2006
31
Cloning, expression, and purification of a highly immunogenic recombinant gonadotropin-releasing hormone (GnRH) chimeric peptide. 9 38
17064933 2006
32
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. 9 38
17062694 2006
33
Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. 9 38
16645169 2006
34
Identification of amino acid residues involved in the interaction between measles virus Haemagglutin (MVH) and its human cell receptor (signaling lymphocyte activation molecule, SLAM). 9 38
16889684 2006
35
The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. 9 38
16782388 2006
36
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. 9 38
16728275 2006
37
Assessment of the performance of a definition of a suspected measles case: implications for measles surveillance. 9 38
16723063 2006
38
Immunosuppression caused by measles virus: role of viral proteins. 9 38
16237742 2006
39
Alterations in cell-mediated immune response in subacute sclerosing panencephalitis. 9 38
16223530 2005
40
Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. 9 38
16260741 2005
41
CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion. 9 38
15920733 2005
42
Evaluation of diagnostic markers for measles virus infection in the context of an outbreak in Spain. 9 38
16207972 2005
43
Gene expression profiles in peripheral blood mononuclear cells from patients with subacute sclerosing panencephalitis using oligonucleotide microarrays. 9 38
16036810 2005
44
Localization of regions in CD46 that interact with adenovirus. 9 38
15919905 2005
45
CD46-independent binding of neisserial type IV pili and the major pilus adhesin, PilC, to human epithelial cells. 9 38
15845515 2005
46
Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? 9 38
15659756 2005
47
Rescue and propagation of fully retargeted oncolytic measles viruses. 9 38
15685166 2005
48
Expression of the interferon-alpha/beta-inducible MxA protein in brain lesions of subacute sclerosing panencephalitis. 9 38
15337611 2004
49
Measles virus receptors: SLAM and CD46. 9 38
15248250 2004
50
Variation in vaccine response in normal populations. 9 38
15165177 2004

Variations for Measles

Expression for Measles

Search GEO for disease gene expression data for Measles.

Pathways for Measles

Pathways related to Measles according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 TLR3 TLR2 STAT1 IFNG IFNB1 IFNAR2
2
Show member pathways
13.27 STAT1 IFNG IFNB1 IFNAR2 HLA-A EIF2AK2
3
Show member pathways
13.02 TLR3 TLR2 STAT1 IFNG IFNB1 IFNAR2
4
Show member pathways
12.93 TLR3 TLR2 STAT1 IFNB1 IFNAR2 HLA-A
5
Show member pathways
12.82 TLR3 TLR2 STAT1 IFNB1 IFNAR2 IFIH1
6
Show member pathways
12.8 STAT1 IFNG IFNAR2 HLA-DMA HLA-A CD40LG
7
Show member pathways
12.7 TLR3 IFNG IFNB1 IFIH1 DDX58 ADAR
8
Show member pathways
12.41 IFNG IFNB1 IFNAR2 HLA-A
9 12.37 TLR3 TLR2 STAT1 IFNG IFIH1 DDX58
10
Show member pathways
12.3 STAT1 IFNG IFNB1 IFNAR2
11
Show member pathways
12.23 STAT1 IFNG IFNB1 IFNAR2
12
Show member pathways
12.2 TLR2 STAT1 IFNG HLA-DMA CD40LG
13
Show member pathways
12.18 STAT1 IFNG IFNB1 IFNAR2 HLA-A ADAR
14 12.12 TLR3 TLR2 STAT1 IFNG
15
Show member pathways
12.12 TLR3 STAT1 IFNG IFNB1 IFNAR2 EIF2AK2
16
Show member pathways
12.11 TLR2 STAT1 IFNG IFNB1
17 12.06 TLR2 HLA-DMA HLA-A FCGR2B CD209
18
Show member pathways
12.05 STAT1 IFNG IFNB1 IFNAR2 HLA-A EIF2AK2
19
Show member pathways
11.99 TLR3 TLR2 STAT1 IFNG
20 11.96 STAT1 IFNG IFNB1 IFNAR2 FCGR2B
21 11.95 TLR2 STAT1 IFNG IFNB1 HLA-DMA FCGR2B
22 11.89 SLAMF1 IFNG CD209
23
Show member pathways
11.87 STAT1 IFNG HLA-A
24 11.81 STAT1 IFNG IFNB1 IFNAR2
25 11.77 TLR2 IFNG HLA-DMA
26 11.71 SLAMF1 IFNG IFNB1 CD209
27
Show member pathways
11.58 IFNG IFNAR2 HLA-A
28 11.47 TLR2 IFNG CD40LG
29 11.3 STAT1 IFNG IFNB1 EIF2AK2
30
Show member pathways
10.38 STAT1 IFNAR2 EIF2AK2 DDX58 ADAR

GO Terms for Measles

Cellular components related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 TLR3 TLR2 IFNAR2 HLA-A FCGR2B CD46
2 cell surface GO:0009986 9.28 TLR3 TLR2 SLAMF1 MSN HLA-DMA HLA-A
3 membrane GO:0016020 10.03 TLR3 TLR2 SLAMF1 NECTIN4 MSN IFNAR2

Biological processes related to Measles according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.97 TLR3 TLR2 SLAMF1 IFIH1 EIF2AK2 DDX58
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 TLR3 TLR2 EIF2AK2 CD40LG
3 viral process GO:0016032 9.91 STAT1 SLAMF1 NECTIN4 IFIH1 FCGR2B EIF2AK2
4 cellular response to interferon-gamma GO:0071346 9.86 TLR3 TLR2 STAT1
5 positive regulation of JNK cascade GO:0046330 9.85 TLR3 SLAMF1 FCGR2B
6 viral entry into host cell GO:0046718 9.85 SLAMF1 NECTIN4 CD46 CD209
7 immune system process GO:0002376 9.85 TLR3 TLR2 SLAMF1 IFIH1 HLA-A EIF2AK2
8 interferon-gamma-mediated signaling pathway GO:0060333 9.84 STAT1 IFNG HLA-A
9 positive regulation of T cell proliferation GO:0042102 9.83 CD46 CD40LG CD209
10 positive regulation of interleukin-6 production GO:0032755 9.83 TLR3 TLR2 DDX58
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.82 TLR3 TLR2 EIF2AK2
12 antigen processing and presentation GO:0019882 9.81 HLA-DMA HLA-A CD209
13 type I interferon signaling pathway GO:0060337 9.8 STAT1 IFNB1 IFNAR2 HLA-A ADAR
14 response to exogenous dsRNA GO:0043330 9.79 TLR3 IFNB1 DDX58
15 positive regulation of interleukin-8 production GO:0032757 9.77 TLR3 TLR2 DDX58
16 leukocyte cell-cell adhesion GO:0007159 9.77 MSN CD40LG CD209
17 positive regulation of interferon-beta production GO:0032728 9.76 TLR3 TLR2 IFIH1 DDX58
18 positive regulation of interleukin-10 production GO:0032733 9.74 TLR2 CD46 CD40LG
19 positive regulation of interleukin-12 production GO:0032735 9.73 TLR3 TLR2 IFNG CD40LG
20 positive regulation of chemokine production GO:0032722 9.71 TLR3 TLR2 EIF2AK2
21 cellular response to interferon-beta GO:0035458 9.7 TLR3 STAT1 IFNB1
22 microglial cell activation GO:0001774 9.69 TLR3 TLR2
23 negative regulation of phagocytosis GO:0050765 9.69 TLR2 FCGR2B
24 positive regulation of interferon-alpha production GO:0032727 9.69 STAT1 IFIH1 DDX58
25 positive regulation of tumor necrosis factor secretion GO:1904469 9.68 IFIH1 DDX58
26 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.68 TLR2 STAT1
27 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.68 STAT1 IFNG
28 I-kappaB phosphorylation GO:0007252 9.68 TLR3 TLR2
29 positive regulation of interferon-alpha secretion GO:1902741 9.67 IFIH1 DDX58
30 response to interferon-beta GO:0035456 9.67 STAT1 IFNAR2
31 response to interferon-alpha GO:0035455 9.67 IFNAR2 EIF2AK2 ADAR
32 cellular response to exogenous dsRNA GO:0071360 9.67 TLR3 IFNB1 IFIH1 DDX58
33 positive regulation of response to cytokine stimulus GO:0060760 9.65 IFIH1 DDX58
34 detection of virus GO:0009597 9.65 TLR3 IFIH1 DDX58
35 positive regulation of interferon-beta secretion GO:0035549 9.64 IFIH1 DDX58
36 positive regulation of toll-like receptor signaling pathway GO:0034123 9.63 TLR3 TLR2
37 interleukin-10 production GO:0032613 9.62 TLR2 CD46
38 regulation of type III interferon production GO:0034344 9.58 IFIH1 DDX58
39 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.58 IFIH1 DDX58
40 response to virus GO:0009615 9.56 TLR3 IFNG IFNB1 IFNAR2 IFIH1 EIF2AK2
41 defense response to virus GO:0051607 9.28 TLR3 STAT1 IFNG IFNB1 IFNAR2 IFIH1
42 immune response GO:0006955 10.08 TLR2 IFNG HLA-DMA HLA-A FCGR2B CD40LG
43 positive regulation of gene expression GO:0010628 10.03 TLR3 TLR2 MSN IFNG DDX58 CD46
44 adaptive immune response GO:0002250 10.02 SLAMF1 IFNG IFNB1 CD46 CD209

Molecular functions related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 TLR3 TLR2 STAT1 SLAMF1 NECTIN4 MYBPH
2 identical protein binding GO:0042802 9.86 TLR3 TLR2 STAT1 SLAMF1 NECTIN4 IFIH1
3 signaling receptor activity GO:0038023 9.72 TLR3 TLR2 SLAMF1 NECTIN4 CD46
4 virus receptor activity GO:0001618 9.46 SLAMF1 NECTIN4 CD46 CD209
5 double-stranded RNA binding GO:0003725 9.1 TLR3 MSN IFIH1 EIF2AK2 DDX58 ADAR

Sources for Measles

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....